Full-Time

Finance Manager / Senior Manager

R&D Finance

Immunome

Immunome

201-500 employees

Antibody-based therapeutic discovery and development

Compensation Overview

$121.5k - $164.4k/yr

Bothell, WA, USA

In Person

Bachelor's, MBA

Category
Accounting (2)
,
Required Skills
NetSuite
Biometrics
Forecasting
Financial analysis
Excel/Numbers/Sheets
Financial Modeling

Get referred to Immunome

See people who can refer or advise you

Requirements
  • A bachelor's degree in Finance, Accounting, or a related field is required.
  • A minimum of 5–8+ years of progressive finance and/or accounting experience is required, including meaningful experience supporting research and development organizations in the life sciences or biotechnology industry, or equivalent experience.
  • Experience in clinical trial finance, clinical accounting, or clinical business operations, with hands-on experience in clinical trial accruals and forecasting, is required or strongly preferred as specified in the posting.
  • Hands-on expertise in clinical trial accruals, forecasting, and financial analysis is required, along with working knowledge of the drug development process, including study start-up, site management, data management, safety reporting, and biometrics.
  • Familiarity with the clinical vendor landscape and outsourcing models, including contract research organizations, central laboratories, imaging vendors, and electronic data capture/data management providers, is required.
  • A strong understanding of United States Generally Accepted Accounting Principles in relation to research and development accounting, accruals, and complex vendor and clinical trial contracts is required, including the ability to report financial information under both GAAP and cash methodologies.
  • Advanced Microsoft Excel and financial modeling skills are required.
  • Public company experience and familiarity with or experience in Sarbanes-Oxley controls and close documentation are required.
  • Experience building and working within budgeting and reporting/planning systems, including building and managing reports, models, and system functionality, is a strong differentiator.
  • Experience with enterprise resource planning systems is preferred.
  • Experience developing tooling and process improvements, including leveraging automation or artificial intelligence to enhance reporting, budgeting and forecasting, and close processes, is required.
  • Strong business partnering and communication skills are required to engage and influence stakeholders across Finance, Clinical Operations, Development, and external vendors.
  • The ability to adapt across areas, learn new responsibilities quickly, and work effectively in a fast-paced, high-growth, changing environment is required.
  • High attention to detail, problem-solving ability, sound judgment when escalating financial risks, and the ability to manage multiple workstreams amid ambiguity are required.
Responsibilities
  • Own the monthly accrual process for an assigned portfolio of clinical trials by understanding study activity and translating it into accurate, supported accruals.
  • Develop and maintain clinical trial forecasts and budgets incorporating enrollment rates, site activations, protocol amendments, vendor activity, and other study changes.
  • Analyze clinical trial expense variances against operational metrics, determine whether variances are temporary or structural, and prepare variance commentary and study-level financial summaries.
  • Partner with Clinical Operations study managers and Development leaders to understand study changes, enrollment challenges, and vendor performance and flag developments with financial implications.
  • Manage purchase orders, contract reconciliation, and vendor invoice issues for assigned studies, partnering with Controllership and Procurement for accurate spend tracking and coding.
  • Prepare month-end close activities, including accruals, journal entries, account reconciliations, and supporting documentation.
  • Perform flux and variance analysis and respond to accounting questions on actuals while ensuring compliance with US GAAP and internal accounting policies.
  • Track department-level purchase orders and expenses during close to ensure complete spend capture.
  • Partner with Accounting to support timely and accurate close processes.
  • Support external audits and reporting by providing documentation, analysis, and commentary.
  • Prepare monthly internal reporting and analysis that contextualizes expenses against operational dynamics.
  • Provide inputs to budgeting, forecasting, and long-range planning for assigned areas at the purchase-order and activity level.
  • Develop models, metrics, reporting templates, and internal benchmarks to improve communication of financial performance.
  • Prepare financial reports and materials for senior leadership highlighting expense trends, risks, and study-level dynamics.
  • Serve as the primary finance business partner and point of contact for assigned R&D functions and processes.
  • Support additional R&D areas, including Discovery, Translational Science, and investigational new drug-enabling program accruals and forecasting.
  • Support R&D departments with operating expense tracking and reporting.
  • Support corporate financial planning and analysis and reporting deliverables, including budget roll-ups, company reporting, and executive- and board-level materials.
  • Improve existing processes and methodologies for functionality, efficiency, and consistency.
  • Contribute to best practices for accrual preparation, clinical financial analysis, variance commentary, and cross-functional reporting.
  • Identify opportunities to use budgeting and reporting systems, automation, artificial intelligence, and other tools to streamline processes and improve reporting.
Desired Qualifications
  • CPA and/or Master of Business Administration is a plus.
  • At least 3 years of experience in clinical trial finance, clinical accounting, or clinical business operations, with hands-on experience in clinical trial accruals and forecasting, is strongly preferred.
  • Understanding of the RFx process is a plus.
  • Experience with enterprise resource planning systems such as NetSuite is preferred.

Immunome identifies antibodies and their targets by studying the immune systems of patients who recover from diseases, to develop first-in-class therapeutics. Its platform analyzes immune responses to discover novel antibodies and their targets, which are then advanced through research and development in partnership with healthcare and medical research clients. The company’s products work by using antibodies discovered from patients’ immune systems to target diseases, potentially enabling new treatments across oncology and other areas. Immunome differentiates itself through a proprietary discovery platform that extracts clinically relevant antibodies from real patient immune responses, enabling collaborations and licensing deals rather than solely pursuing standalone drug sales. The goal is to bring new antibody therapies to patients by forming partnerships, licensing innovations, and eventually delivering approved therapies.

Company Size

201-500

Company Stage

IPO

Headquarters

Bothell, Washington

Founded

2008

Get referred to Immunome

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • FDA set varegacestat's PDUFA date for April 28, 2027 after strong Phase 3 data.
  • Cash and marketable securities totaled $520.0 million on June 30, 2026, funding into 2028.
  • IM-1617's first patient dosing on June 11, 2026 expands multiple shots on goal.

What critics are saying

  • IM-1617 faces AbbVie's ABBV-400 and Daiichi's crowded TOP1 ADC category by 2027.
  • Immunome burned $120.3 million cash in first-half 2026, despite $520.0 million remaining.
  • A varegacestat rejection would leave Immunome dependent on early-stage programs and recurring dilution.

What makes Immunome unique

  • Varegacestat reached FDA acceptance in July 2026, anchoring Immunome's first near-term asset.
  • IM-1617 targets an undisclosed RTK plus immune exclusion, a rare dual-mechanism ADC.
  • IM-1021 and IM-3050 broaden the platform across ADC and radioligand modalities.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

401(k) Company Match

Unlimited Paid Time Off

Hybrid Work Options

Flexible Work Hours

Remote Work Options

Paid Vacation

Paid Holidays

Wellness Program

Mental Health Support

Conference Attendance Budget

Professional Development Budget

Stock Options

Company Equity

Phone/Internet Stipend

Home Office Stipend

Growth & Insights and Company News

Headcount

6 month growth

21%

1 year growth

21%

2 year growth

9%
Associated Press
Aug 11th, 2026
Immunome's varegacestat NDA accepted by FDA with April 2027 target date, $520M cash reserves

Immunome reported Q2 2026 financial results, revealing a net loss of $73.1 million. The biotechnology company held $520.0 million in cash, cash equivalents and marketable securities as of 30 June, expected to fund operations into 2028. The FDA accepted Immunome's application for varegacestat, a desmoid tumour treatment, setting an approval decision date of 28 April 2027. Phase 3 trial data showed an 84% reduction in disease progression risk versus placebo. Research and development expenses totalled $59.9 million for the quarter, whilst general and administrative costs reached $18.3 million. Immunome is advancing three additional clinical-stage programmes, with first patients dosed in trials for IM-1617 and IM-3050. The company plans to submit investigational new drug applications for IM-1340 and IM-1335 by late 2026.

AllSci
Jun 12th, 2026
Immunome debuts first-in-class ADC targeting mystery immune-excluding receptor tyrosine kinase.

Immunome debuts first-in-class ADC targeting mystery immune-excluding receptor tyrosine kinase. June 12, 2026 Bothell, Washington-based Immunome, Inc. (Nasdaq: IMNM) has dosed the first patient in a Phase I first-in-human study of IM-1617, an antibody-drug conjugate directed at an undisclosed receptor tyrosine kinase (RTK) and armed with HC74, the company's proprietary topoisomerase I inhibitor payload. The trial's significance lies partly in its target biology: the RTK in question is described as promoting tumor cell survival while simultaneously mediating immune cell exclusion - a dual role that, if confirmed clinically, could position IM-1617 as relevant in immunologically cold tumors where checkpoint inhibitors have largely failed. The open-label, multicenter dose escalation and expansion study will enroll patients with advanced solid tumors, including colorectal cancer, non-small cell lung cancer, and breast cancer. Primary objectives cover safety, tolerability, and pharmacokinetics, with preliminary anti-tumor activity as an exploratory endpoint. Immunome has not disclosed enrollment targets or an anticipated completion date. Two additional ADC candidates - IM-1340 and IM-1335 - are expected to reach IND submission by mid- and late 2026, respectively, signaling broader platform ambitions beyond this single asset. The rationale for IM-1617 rests on a well-documented but therapeutically underexploited observation: certain receptor tyrosine kinases do not merely sustain tumor cell proliferation but actively remodel the tumor microenvironment to prevent T-cell infiltration. The TAM family RTKs - TYRO3, AXL, and MERTK - are the best-characterized examples, functioning as innate immune checkpoints that suppress dendritic cell and macrophage activity while driving tumor cell survival through PI3K/AKT and RAS/MAPK signaling. AXL in particular has been directly implicated in T-cell exclusion in breast cancer models, where high AXL expression correlated with complete absence of immune infiltration even following radiotherapy. This biology is directly relevant to the three indications Immunome has identified. Approximately 85% of colorectal cancers are microsatellite-stable and immunologically cold, explaining why PD-1/PD-L1 inhibitors have shown no benefit in this population. A comparable subset of non-small cell lung cancers and triple-negative breast cancers similarly fail to respond to immunotherapy, not because of absent antigenicity but because immune cells are physically excluded from the tumor parenchyma. An ADC targeting the RTK responsible for that exclusion could, in principle, simultaneously kill antigen-expressing tumor cells and relieve the suppressive barrier - potentially rendering surviving tumor tissue more susceptible to endogenous or therapeutically induced immune responses. Competitive positioning. The TOP1 inhibitor ADC space is crowded at the payload level but less so at the target level, where differentiation ultimately resides. Daiichi Sankyo and AstraZeneca's DXd platform dominates across HER2, HER3, and TROP2, with multiple Phase II and Phase III assets in NSCLC and breast cancer. AbbVie is advancing ABBV-400, a c-MET-targeted ADC with a proprietary TOP1 inhibitor payload, in NSCLC and colorectal cancer - indications that directly overlap with IM-1617's target population. Because IM-1617's RTK target remains undisclosed, precise competitive mapping is not possible, but the functional description - an RTK driving both survival signaling and immune exclusion - most closely resembles AXL or MERTK biology, neither of which currently has a clinical-stage ADC program of note. Immunome's broader pipeline context is relevant here. Varegacestat, the company's gamma secretase inhibitor for desmoid tumors, has an NDA filed with the US FDA following Phase III data showing 84% reduction in progression risk and a 56% objective response rate - substantially outperforming the current standard. That near-term commercial asset provides a degree of financial and strategic runway for the ADC platform to mature. IM-1021, the ROR1 ADC sharing the HC74 payload with IM-1617, will generate the first human pharmacokinetic and safety data for HC74, which will inform dose selection and linker optimization for subsequent programs including IM-1617. This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: https://allsci.com/news/

Business Wire
May 12th, 2026
Immunome submits NDA for varegacestat after 84% disease progression reduction in Phase 3 trial

Immunome, a biotechnology company developing targeted cancer therapies, reported first quarter 2026 financial results. The company had cash and cash equivalents of $582.7 million as of 31 March, expected to fund operations into 2028. The company submitted a New Drug Application to the US FDA in April 2026 for varegacestat, a treatment for adults with desmoid tumours. Immunome plans to submit a Marketing Authorisation Application to the European Medicines Agency by year-end 2026. Research and development expenses for the quarter were $46.4 million, whilst general and administrative expenses totalled $13.0 million. Immunome reported a net loss of $53.8 million for the quarter. The company is advancing multiple programmes, including Phase 1 trials for IM-1021 and IM-3050, and recently received IND clearance for IM-1617.

Yahoo Finance
Apr 4th, 2026
Immunome CSO sells $204K in shares ahead of Q2 2026 NDA submission

Immunome's Chief Scientific Officer Jack Higgins sold 9,438 shares on 2 April for $204,238, reducing his direct holdings by 30% to 22,000 shares. The sale was executed under a pre-arranged Rule 10b5-1 trading plan established in December 2025 for financial diversification. The transaction comes as the clinical-stage biotechnology company approaches a significant milestone: its lead candidate varegacestat met the primary endpoint in a Phase 3 trial in December 2025, with an FDA submission planned for the second quarter of 2026. Immunome expects three additional investigational new drug applications and early data from IM-1021 across 2026. The company's stock has risen 250% over the past year, bringing its market capitalisation to $2.40 billion.

Yahoo Finance
Mar 6th, 2026
Immunome cuts 2025 net loss to $212M, files $156M shelf registration ahead of varegacestat NDA

Immunome has reported a reduced full-year net loss of $212.39 million for 2025 and filed a $156.03 million common stock shelf registration linked to an employee stock option plan offering. The biotechnology company also updated investors on progress in its oncology pipeline. The company plans to file a New Drug Application for varegacestat following positive Phase 3 data, with multiple solid tumour investigational new drug applications also in development. However, Immunome remains deeply unprofitable despite the narrower losses. The shelf registration raises concerns about potential equity dilution and ownership overhang. Fair value estimates from analysts vary widely, ranging from approximately $29 to over $215 per share, reflecting significant uncertainty around the company's prospects as it advances its high-risk oncology platform.